Yat Sun Or
2013
In 2013, Yat Sun Or earned a total compensation of $992.8K as Senior Vice President, Research & Development and Chief Scientific Officer at Enanta Pharmaceuticals, a 64% increase compared to previous year.
Compensation breakdown
Bonus | $143,174 |
---|---|
Option Awards | $501,973 |
Salary | $343,255 |
Other | $4,439 |
Total | $992,841 |
Or received $502K in option awards, accounting for 51% of the total pay in 2013.
Or also received $143.2K in bonus, $343.3K in salary and $4.4K in other compensation.
Rankings
In 2013, Yat Sun Or's compensation ranked 6,646th out of 12,286 executives tracked by ExecPay. In other words, Or earned more than 45.9% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 6,646 | 46th |
Manufacturing | 2,341 | 49th |
Chemicals And Allied Products | 697 | 53rd |
Drugs | 509 | 56th |
Pharmaceutical Preparations | 402 | 55th |
Or's colleagues
We found two more compensation records of executives who worked with Yat Sun Or at Enanta Pharmaceuticals in 2013.
News
Enanta Pharmaceuticals CEO Jay Luly's 2022 pay jumps 37% to $7.3M
January 20, 2023
Enanta Pharmaceuticals CEO Jay Luly's 2021 pay rises 2% to $5.3M
January 21, 2022
Enanta Pharmaceuticals CEO Jay Luly's 2020 pay rises 16% to $5.2M
January 21, 2021
Enanta Pharmaceuticals CEO Jay Luly's 2019 pay slips 1% to $4.5M
January 17, 2020
Enanta Pharmaceuticals CEO Jay Luly's 2018 pay rises 5% to $4.5M
January 18, 2019